Head and Neck Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Cancer Med. 2024 Jun;13(11):e7350. doi: 10.1002/cam4.7350.
High-grade glioma (HGG) is known to be characterized by a high degree of malignancy and a worse prognosis. The classical treatment is safe resection supplemented by radiotherapy and chemotherapy. Tumor treating fields (TTFields), an emerging physiotherapeutic modality that targets malignant solid tumors using medium-frequency, low-intensity, alternating electric fields to interfere with cell division, have been used for the treatment of new diagnosis of glioblastoma, however, their administration in HGG requires further clinical evidence. The efficacy and safety of TTFields in Chinese patients with HGG were retrospectively evaluated by us in a single center.
We enrolled and analyzed 52 patients with newly diagnosed HGG undergoing surgery and standard chemoradiotherapy regimens from December 2019 to June 2022, and followed them until June 2023. Based on whether they used TTFields, they were divided into a TTFields group and a non-TTFields group. Progression-free survival (PFS) and overall survival (OS) were compared between the two groups.
There were 26 cases in the TTFields group and 26 cases in the non-TTFields group. In the TTFields group, the median PFS was 14.2 months (95% CI: 9.50-18.90), the median OS was 19.7 months (95% CI: 14.95-24.25) , the median interval from surgery to the start of treatment with TTFields was 2.47 months (95% CI: 1.47-4.13), and the median duration of treatment with TTFields was 10.6 months (95% CI: 9.57-11.63). 15 (57.69%) patients experienced an adverse event and no serious adverse event was reported. In the non-TTFields group, the median PFS was 9.57 months (95% CI: 6.23-12.91) and the median OS was 16.07 months (95% CI: 12.90-19.24). There was a statistically significant difference in PFS (p = 0.005) and OS (p = 0.007) between the two groups.
In this retrospective analysis, TTFields were observed to improve newly diagnosed HGG patients' median PFS and OS. Compliance was much higher than reported in clinical trials and safety remained good.
高级别胶质瘤（HGG）以高度恶性和预后不良为特征。经典治疗是安全切除辅以放疗和化疗。肿瘤治疗电场（TTFields）是一种新兴的物理治疗方法，通过使用中频、低强度、交替电场靶向恶性实体瘤来干扰细胞分裂，已用于治疗新诊断的胶质母细胞瘤，但在 HGG 中的应用需要更多的临床证据。我们在一家中心对接受手术和标准放化疗方案治疗的 52 例新诊断的 HGG 患者进行了 TTFields 的回顾性疗效和安全性评估，并随访至 2023 年 6 月。根据是否使用 TTFields，将患者分为 TTFields 组和非 TTFields 组。比较两组患者的无进展生存期（PFS）和总生存期（OS）。
纳入并分析了 2019 年 12 月至 2022 年 6 月期间接受手术和标准放化疗方案治疗的 52 例新诊断的 HGG 患者，并随访至 2023 年 6 月。根据是否使用 TTFields，将患者分为 TTFields 组和非 TTFields 组。比较两组患者的无进展生存期（PFS）和总生存期（OS）。
TTFields 组 26 例，非 TTFields 组 26 例。TTFields 组的中位 PFS 为 14.2 个月（95%CI：9.50-18.90），中位 OS 为 19.7 个月（95%CI：14.95-24.25），从手术到开始 TTFields 治疗的中位间隔时间为 2.47 个月（95%CI：1.47-4.13），TTFields 治疗的中位持续时间为 10.6 个月（95%CI：9.57-11.63）。15 例（57.69%）患者出现不良事件，无严重不良事件报告。非 TTFields 组的中位 PFS 为 9.57 个月（95%CI：6.23-12.91），中位 OS 为 16.07 个月（95%CI：12.90-19.24）。两组患者的 PFS（p=0.005）和 OS（p=0.007）差异有统计学意义。
在这项回顾性分析中，TTFields 观察到可改善新诊断的 HGG 患者的中位 PFS 和 OS。依从性远高于临床试验报道的水平，安全性仍然良好。
